Glenmark will commercialize the combination under the brand names ‘Remo-M’ and ‘Remozen-M’
Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate in India
and became the first company in the world to launch Remogliflozin with India being the first country
to get access to this innovative drug
Remogliflozin is an innovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor
indicated in treatment of type-2 diabetes mellitus in adults
Mumbai, India; August 19, 2019: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led
global integrated pharmaceutical company, today announced that the company has received regulatory
approval to market a combination of its novel, patent protected and globally-researched sodium glucose
co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride
(Metformin) film coated tablets in India. The drug is indicated in the treatment of type-2 diabetes mellitus
in adults. Glenmark will commercialize the product under the brand names ‘Remo-M’ and Remozen-M’.
Earlier in April 2019, Glenmark received regulatory approval for Remogliflozin etabonate 100 mg tablets,
twice daily, after successfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good
efficacy and safety profile in a head-to-head comparison against Dapagliflozin. With this approval
Glenmark became the first company in the world to launch the novel SGLT2 inhibitor Remogliflozin with
India being the first country to get access to this innovative drug. Glenmark subsequently launched
Remogliflozin in India under the brand names ‘Remo’ and ‘Remozen’.
Glenmark has now received regulatory approval for a combination of Remogliflozin and Metformin film
coated tablets. The approved dosage strengths are 100 mg of Remogliflozin combined with either 500 mg
or 1,000 mg of Metformin. This combination is indicated as an adjunct to diet and exercise to improve
glycemic control in type-2 diabetes mellitus patients (for full indication, it is advisable to refer the package
“The approval for Remogliflozin and Metformin combination is a testament of our commitment towards
revolutionizing diabetes management in India. Glenmark is a pioneer in providing access to the latest
treatment options to diabetes patients in India. Earlier this year, we launched Remogliflozin with an aim
to increase patients’ access to SGLT2 inhibitors as this class of drugs have proven benefits for effective
diabetes management. As the prevalence of diabetes continues to rise rapidly, we are pleased to offer an
additional treatment option to patients. This approval for combination of Remogliflozin and Metformin
will only help us get closer to our goal of providing an effective, high quality and world-class treatment
option and improving access to SGLT2 inhibitors for patients in India,” said Sujesh Vasudevan, President,
India Formulations, Middle East and Africa at Glenmark Pharmaceuticals.
The company had launched Remogliflozin as a mono-therapy, at a breakthrough price which is over 50%
lower than the existing SGLT2 inhibitors available in India. Prior to the launch of Remogliflozin, the
average per day therapy cost of SGLT2 inhibitors in India was about Rs. 55.
Remogliflozin has been studied in 26 clinical trials globally, covering around 2,500 patients from various ethnicities. Glenmark
secured certain rights to Remogliflozin through a licensing collaboration agreement with a subsidiary of Avolynt, Inc. which is
based in North Carolina, USA, and conducted the Phase-3 clinical trial, which included the largest number of Indian patients
tested for any SGLT2 inhibitor.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among
the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018).
Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological
entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology,
dermatology and respiratory.
The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark
has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the
requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the
US, various countries in the EU, South America and India.
For further information, please contact:
Glenmark, Mumbai, India
Tel: +91 22 4018 9999